Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | NMT2 | O60551 | 1/20 | 0.49 |
| ▸ | NMT1 | P30419 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 5/20 | 0.48 |
| ▸ | CDK4 | P11802 | 5/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.48 |
| ▸ | CCND1 | P24385 | 5/20 | 0.48 |
| ▸ | CDK2 | P24941 | 5/20 | 0.48 |
| ▸ | CCND3 | P30281 | 5/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5952326 | 0.88 | NMT1 (0.50) | NPC1RAB9ASMN1; SMN2NMT1KDR | |
| SCHEMBL5951245 | 0.87 | KDR (0.49) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL5951740 | 0.87 | PDE10A (0.49) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL5952686 | 0.85 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL5951759 | 0.84 | PDE10A (0.49) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL4916396 | 0.84 | PDE10A (0.53) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL5952146 | 0.84 | PDE10A (0.53) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL5953158 | 0.83 | PDE10A (0.51) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL5952104 | 0.81 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2KDRCDK4 | |
| SCHEMBL5951223 | 0.81 | MEN1 (0.50) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | claimed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | claimed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | claimed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | claimed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | NPC1 3302/4885RAB9A 810/4885SMN1; SMN2 4210/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | NPC1 2551/4885RAB9A 955/4885SMN1; SMN2 3516/4885 |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | KDR, MUSK, FLT4 | NPC1 4816/4885RAB9A 3809/4885SMN1; SMN2 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.